Do GLP-1 agonists like Wegovy (semaglutide) help with high blood pressure?

Semaglutide, currently sold as Wegovy (for obesity) or Ozempic (for diabetes), is being hyped by various public figures as the new miracle weight-loss drug. Novo Nordisk, the maker of Wegovy, even became the most valuable company in Europe in early September 2023 thanks to the "miracle injection." This is relevant for people with high blood pressure because Wegovy can be prescribed from a BMI of 30. If there are weight-related conditionssuch as high blood pressureit can be prescribed from a BMI of 27. At a height of 1.75 m, a weight of 82.5 kg already gives a BMI of 27. We have a separate article on BMI and how to calculate it.

But does semaglutide really live up to the promises of an easy route to weight loss?

Semaglutide for diabetes

Semaglutide was originally developed to treat type 2 diabetes. This common lifestyle-related form of diabetes is considered acquiredcaused by an unhealthy diet and too little exerciseand was formerly called adult-onset diabetes. Nowadays more younger people and even children are affected. Semaglutide products are an alternative to existing diabetes medications and can be used when other options are not tolerated or dont work well enough.

Semaglutide for weight loss

The drug has also been shown to be effective for weight loss. Patients treated with it not only improved their blood sugar levels but also lost weight. For that reason, higher-dose semaglutide has been approved as an adjunct treatment for obesity (BMI 30 or more) or for overweight (BMI 27 or more) when there are accompanying weight-related conditions such as high blood pressure. "Adjunct" means the drug doesn't play the main role in treatment but supports basic measures like changing diet, increasing exercise, and modifying behavior when those measures alone aren't enough. The drug can be prescribed in these cases, but patients usually have to pay for it themselves. It's injected once a week and will probably need to be continued long-term, because weight often returns after stopping. That shows how important lifestyle change isonly that can help keep weight down in the long run.

How does semaglutide work?

Semaglutide is a drug that mimics the effect of the body's own hormone GLP-1. GLP-1 is a peptide hormone that helps regulate blood sugar. It stimulates insulin release and suppresses glucagon, a hormone that raises blood sugar. It also slows stomach emptying and increases feelings of fullness. Semaglutide is a synthetic GLP-1 receptor agonist, meaning it binds to and activates the same receptor as GLP-1. Unlike natural GLP-1, which is broken down quickly in the body, semaglutide has a longer half-life and therefore acts longer. This explains semaglutide's weight-reducing effect, since it suppresses appetite and reduces calorie intake. As with other weight-loss drugs, semaglutide can cause side effects, mainly in the gastrointestinal tract, such as nausea and diarrhea. The long-term effects and risks of semaglutide are not yet fully understood.

Semaglutide for high blood pressure

The positive effect on blood pressurethat is, the blood-pressure-lowering effectis attributed to the weight loss. A direct effect on blood pressure has not been demonstrated so far. Nevertheless, blood pressure should be monitored, because, as described, it can falland that may require adjusting blood pressure medication.

So the foundation remains changing ones own behaviordiet, activity, and certain habitstoward an overall healthier lifestyle to keep weight down long-term and to protect against weight-related complications. Semaglutide can support these efforts. But, like many formerly hyped weight-loss drugs, it is not a miracle cure for losing weight.

Other GLP-1 analogs

Besides semaglutide, there are other so-called GLP-1 analogs. For example, tirzepatide (in Mounjaro), liraglutide (in Saxenda and Victoza), or dulaglutide (in Trulicity). Other agents include albiglutide, exenatide, and lixisenatide. There are already studies looking at their effects on blood pressure. For example, a study on tirzepatide was published in February 2024. The results are promising, although the effect is at least partly due to weight loss.

Sources:

https://www.aerzteblatt.de/nachrichten/145222/Die-Medikamente-muessen-mehr-Effekte-zeigen-als-nur-den-Gewichtsverlust
https://www.aerzteblatt.de/archiv/212727/Typ-2-Diabetes-Glukosesenkung-mit-Herzschutz
https://adipositas-gesellschaft.de/adipositas-medikamente-fragen-und-antworten/
https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
https://www.nejm.org/doi/full/10.1056/nejmoa1607141
https://www.ema.europa.eu/en/documents/overview/wegovy-epar-medicine-overview_de.pdf
https://www.aerzteblatt.de/nachrichten/145163/Adipositas-Semaglutid-senkt-Zahl-der-Herz-Kreislauf-Ereignisse
https://www.pharmazeutische-zeitung.de/wegovy-ab-heute-in-deutschland-erhaeltlich-141242/
https://www.aerzteblatt.de/archiv/196360/Adipositastherapie-Abnehmen-mittels-Medikament
https://flexikon.doccheck.com/de/GLP-1-Rezeptor-Agonist
https://www.msdmanuals.com/de-de/profi/klinische-pharmakologie/pharmakodynamik/arzneimittel-rezeptor-wechselwirkungen
https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.123.22022
https://www.pharmazeutische-zeitung.de/ema-entscheidung-mit-beigeschmack-149105/
https://www.aerzteblatt.de/nachrichten/156988/GLP-1-Rezeptoragonisten-zeigen-verschiedene-positive-Effekte-aber-auch-Risiken

This article comes from BloodPressureDB – the leading app since 2011 that helps hundreds of thousands monitor their blood pressure every day. Our content is based on carefully researched, evidence-based data and is continuously updated (as of 12/2025).

Author Sabine Croci is a qualified medical assistant with many years of experience in internal medicine and cardiology practices as well as in outpatient care, and has led BloodPressureDB's specialist editorial team since 2015. Thanks to her extensive additional qualifications as a paramedic, first responder and in various therapy and emergency areas, she provides solid, practical and reliably reviewed information.